Don’t miss the latest developments in business and finance.

Suven Life Sciences secures product patents in Israel and Japan

Image
Capital Market
Last Updated : Nov 06 2018 | 11:04 AM IST

On 06 November 2018

Suven Life Sciences announced that the grant of 1 product patent from Israel (255994) and 1 product patent from Japan (6397131) corresponding to the New Chemical Entities for treatment of disorders associated with Neurodegenerative diseases are valid through 2036 and 2034 respectively. The granted claims of the patents include the class of selective M1 PAM and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as treatment of cognitive impairment associated with eurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia etc.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Nov 06 2018 | 10:35 AM IST

Next Story